Komori
Disclosure4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Notice Regarding the Refinancing of Existing Borrowings Through a Bridge Loan

The Company has decided to repay in full its existing borrowings guaranteed by SUMITOMO CHEMICAL COMPANY,LIMITED and refinance them through bridge loans without such guarantees. The new bridge loans will consist of term loans to fund the refinancing of the existing borrowings and a commitment line for working capital.

Worth reading
70In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Decision and Details

Refinancing of existing borrowings through bridge loans

Decision8 April 2026
Period Covered24 April 2026 to 23 April 2027
Implementation24 April 2026 (scheduled; the start date of the borrowing period and commitment period)
Going forwardThe borrowing period and commitment period for this bridge loan will begin on 24 April 2026, and the loan will be repaid in a lump sum at maturity on 23 April 2027.
AmountThis bridge loan: term loans totaling ¥20 billion and a commitment line totaling ¥130 billion. Outstanding principal balance of the existing syndicated loan to be repaid (as of 8 April 2026): term loans of ¥60 billion and a commitment line of ¥38.1 billion
Reason

In connection with the issuance of new shares and the offering of the Company's shares, the Company will repay in full its existing borrowings guaranteed by SUMITOMO CHEMICAL COMPANY,LIMITED and refinance them through this bridge loan without a guarantee from SUMITOMO CHEMICAL COMPANY,LIMITED.

Impact on Business Performance

The impact on consolidated results for the fiscal year ending March 2027 will be minor.

Decision and Details
ItemDetails
Matter CoveredRefinancing of existing borrowings through bridge loans
Decision Date8 April 2026
Implementation Date24 April 2026 (scheduled; the start date of the borrowing period and commitment period)
Period Covered24 April 2026 to 23 April 2027
AmountThis bridge loan: term loans totaling ¥20 billion and a commitment line totaling ¥130 billion. Outstanding principal balance of the existing syndicated loan to be repaid (as of 8 April 2026): term loans of ¥60 billion and a commitment line of ¥38.1 billion
Impact on Business PerformanceThe impact on consolidated results for the fiscal year ending March 2027 will be minor.
ReasonIn connection with the issuance of new shares and the offering of the Company's shares, the Company will repay in full its existing borrowings guaranteed by SUMITOMO CHEMICAL COMPANY,LIMITED and refinance them through this bridge loan without a guarantee from SUMITOMO CHEMICAL COMPANY,LIMITED.
Related previous disclosures“Notice Regarding Refinancing of Existing Borrowings Through a Syndicated Loan” dated 26 March 2025, and “Notice Regarding the Issuance of New Shares and Offering of Shares” dated 8 April 2026
Future plansThe borrowing period and commitment period for this bridge loan will begin on 24 April 2026, and the loan will be repaid in a lump sum at maturity on 23 April 2027.
Items this document does not state (3)
Decision-Making BodyQuantity / scaleGoverning Rule

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In connection with the issuance of new shares and the offering of the Company's shares, the Company will repay in full its existing borrowings guaranteed by SUMITOMO CHEMICAL COMPANY,LIMITED and refinance them through bridge loans without guarantees from SUMITOMO CHEMICAL COMPANY,LIMITED.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Refinancing of Existing Borrowings Through a Bridge Loan | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori